Skip to main content
Premium Trial:

Request an Annual Quote

CORRECTION: Gates Foundation, Synlogic Collaborate On Technology Application

GenomeWeb Daily News was provided incorrect information that the $5 million was in addition to the $29.4 million that Synlogic raised in July. The summer financing included the $5 million.

NEW YORK (GenomeWeb) – Synthetic biology firm Synlogic today announced it and the Bill & Melinda Gates Foundation will collaborate as part of a $5 million investment from the foundation into Synlogic's Series A financing round in July that raised $29.4 million.

Synlogic previously announced that Atlas Venture and New Enterprise Associates invested in the Series A round. The Cambridge, Mass.-based firm today said that along with developing its technology platform and therapeutic applications, it will collaborate with the Gates Foundation on applications for its technology that are relevant to the developing world.

Synlogic's technology is based on bacteria that sense physiologic changes, perform a therapeutic action, and then deactivate themselves. In a statement, Trevor Mundel, president of global health for the Gates Foundation, said that the firm's technology could result in new therapies for the most severe diarrheal diseases, the second-leading cause of death for children in developing nations.

Synlogic also announced Paul Miller has joined the company as CSO and Alison Silva has joined it as Chief Operating Officer.